2017 was an exciting year for the tech sector, especially the FAANG stocks. Lindsey Bell, Investment Strategist for CFRA, and Ryan Vlastelica, Reporter at MarketWatch, join The Long and The Short to discuss the year's ups and downs.
Bell believes Facebook and Netflix had the best year out of all the FAANG stocks. She predicts that because our lives are becoming more and more connected, Facebook, Apple, Amazon, Netflix, and Google will continue to outperform in the coming year. However, Vlastelica says investors should be wary of FAANG stocks going into 2018. Since they are such huge tech companies they are more vulnerable to a market crash.
Plus, how Tesla, Square, and Nvidia made a comeback after the fall tech sell-off. Vlastelica says Square is on an upswing because it's now offering options to pay in Bitcoin, which is a hot, trending cryptocurrency. As far as Tesla, CFRA has a "sell" rating on it, citing that it's overvalued amid increasing competition.
The Week's Top Stories is a guided tour through the biggest market stories of the week, from winning stocks to brutal dips to the facts and forecasts generating buzz on Wall Street.
Federal Reserve Chair Jerome Powell was tricked into an extended phone call in January with Russian pranksters posing as Ukrainian President Volodymyr Zelenskyy, during which Powell appeared to discuss the economic impact of interest rate hikes.
Amazon on Thursday reported stronger-than-expected revenue and profits for the first quarter, sending its stocks higher in after-hours trading. But its prices took a dip in the evening amid concerns about a continued slowdown in the company's profitable cloud computing unit AWS.
A key index of underlying inflation that is closely followed by the Federal Reserve remained elevated last month, keeping the Fed on track to raise interest rates next week for the 10th time since March of last year.
As a growing number of overweight Americans clamor for Ozempic and Wegovy — drugs touted by celebrities and on TikTok to pare pounds — an even more powerful obesity medicine is poised to upend treatment.
